Several small molecular fluorescent probes utilizing above strategy have been developed for the selective recognition of NADH. To mention a few, Dwivedi Different drugs are known in literature for inactivation of glycolysis pathway. 3-Bromopyruvic acid (3-BrPA) is one of the antiglycolytic drug known to induce cancer cell death by inactivating the essential enzymes of the glycolysis pathway. On of the essential enzymes of glycolysis pathway is GAPDH which is involved in the conversion of glyceraldehyde-3phosphate to 1,3-bisphosphoglycerate and subsequently leads to the generation of NADH. In the presence of 3-BrPA, there occurs covalent modification of GAPDH due to addition of pyruvyl moiety and results in loss of enzymatic function of GAPDH and induces cancer cell death. Hence, the presence of 3-BrPA leads to reduced GAPDH levels in the cells which in turn leads to decrease in NADH levels. We have explored MQ-CN-BTZ as molecular probe for imaging the event of glycolysis in cellular system in the presence of 3-BrPA. Overall, the present study demonstrates the potential of suitable fluorescent probe for dual channel imaging of modulation of NADH levels in the cells in the presence of 3-BrPA as glycolytic inhibitor. Similarly, in the absence of NADH, the probe exhibited a weak fluorescence peak at 523 nm. However, with the addition of NADH (300 μM), the probe showed a unique dual emissive characteristic with peaks at 529 and 656 nm, respectively, when excited at 475 nm (Fig. ). While the weak emission in the green region (~529 nm) seems to be due to the intramolecular charge transfer (ICT), the strong emission in the far-red region at ~656 nm was possibly due to the aggregated state of the probe (Fig. ) in the resulting environment.